Difference between revisions of "Veltuzumab (hA20)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) m (Text replacement - "5 PubMed" to "5/ PubMed") |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Humanized monoclonal anti-CD20 antibody, which binds to cells expressing CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35). Veltuzumab has been observed to have apoptotic, anti-proliferative, and antibody-dependent cellular cytotoxic (ADCC) effects.<ref>[http://www.immunomedics.com/veltuzumab.shtml Veltuzumab (hA20) manufacturer's website]</ref><ref>Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009 Jan 29;113(5):1062-70. Epub 2008 Oct 21. [http://www.bloodjournal.org/content/113/5/1062.long link to original article] [https:// | + | Class/mechanism: Humanized monoclonal anti-CD20 antibody, which binds to cells expressing CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35). Veltuzumab has been observed to have apoptotic, anti-proliferative, and antibody-dependent cellular cytotoxic (ADCC) effects.<ref>[http://www.immunomedics.com/veltuzumab.shtml Veltuzumab (hA20) manufacturer's website]</ref><ref>Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009 Jan 29;113(5):1062-70. Epub 2008 Oct 21. [http://www.bloodjournal.org/content/113/5/1062.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/18941114/ PubMed]</ref><ref>Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009 Jul 10;27(20):3346-53. Epub 2009 May 18. [https://doi.org/10.1200/jco.2008.19.9117 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19451441/ PubMed]</ref><ref>Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010 May;51(5):747-55. [https://doi.org/10.3109/10428191003672123 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20214444/ PubMed]</ref><ref>Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica. 2011 Apr;96(4):567-73. Epub 2010 Dec 20. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069234/ link to original article] [https://pubmed.ncbi.nlm.nih.gov/21173095/ PubMed]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 10: | Line 10: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' IMMU-160 | + | *'''Code name:''' hA20, IMMU-160 |
==References== | ==References== | ||
Revision as of 21:25, 1 May 2023
General information
Class/mechanism: Humanized monoclonal anti-CD20 antibody, which binds to cells expressing CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35). Veltuzumab has been observed to have apoptotic, anti-proliferative, and antibody-dependent cellular cytotoxic (ADCC) effects.[1][2][3][4][5]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
No information available.
Also known as
- Code name: hA20, IMMU-160
References
- ↑ Veltuzumab (hA20) manufacturer's website
- ↑ Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, Hansen HJ, Chang CH. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood. 2009 Jan 29;113(5):1062-70. Epub 2008 Oct 21. link to original article PubMed
- ↑ Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol. 2009 Jul 10;27(20):3346-53. Epub 2009 May 18. link to original article PubMed
- ↑ Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma. 2010 May;51(5):747-55. link to original article PubMed
- ↑ Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, Teoh N, Horne H, Wegener WA, Goldenberg DM. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica. 2011 Apr;96(4):567-73. Epub 2010 Dec 20. link to original article PubMed